Search

Your search keyword '"MESH : Cancer Vaccines"' showing total 6 results
Start Over Descriptor "MESH : Cancer Vaccines" Publisher hal ccsd
6 results on '"MESH : Cancer Vaccines"'

1. Autoimmune mediated regulation of ovarian tumor growth

Author

Vincent K. Tuohy, Cengiz Z. Altuntas, Ritika Jaini, Daniel Jane-wit, Pavani Kesaraju, Christopher A. Flask, Jean Yves Picard, Martin Dutertre, Kelly K Covey, Justin M. Johnson, Lerner Research Institute, Cleveland Clinic, Equipe 7, Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Endocrinologie et Génétique de la Reproduction et du Développement, Université Paris-Sud - Paris 11 (UP11)-IFR13-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Recherche en Cancérologie de Lyon ( CRCL ), Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ) -Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), and Université Paris-Sud - Paris 11 ( UP11 ) -IFR13-Institut National de la Santé et de la Recherche Médicale ( INSERM )

Subjects
MESH : Molecular Sequence Data, endocrine system diseases, Autoimmunity, MESH: Amino Acid Sequence, medicine.disease_cause, HER2/neu, MESH: Cancer Vaccines, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, Ovarian tumor, Mice, 0302 clinical medicine, MESH: Autoimmune Diseases, MESH : Autoimmunity, MESH : Female, MESH: Animals, MESH: Peptide Fragments, Ovarian Neoplasms, 0303 health sciences, biology, MESH : Amino Acid Sequence, MESH : Cancer Vaccines, Obstetrics and Gynecology, Anti-Müllerian hormone, MESH : Mice, Transgenic, female genital diseases and pregnancy complications, 3. Good health, Premature ovarian failure, MESH: Ovarian Neoplasms, medicine.anatomical_structure, Oncology, 030220 oncology & carcinogenesis, MESH: Cell Growth Processes, Female, endocrine system, MESH: Mice, Transgenic, Molecular Sequence Data, Ovary, Mice, Transgenic, [SDV.CAN]Life Sciences [q-bio]/Cancer, Cell Growth Processes, MESH : Mice, Inbred C57BL, Cancer Vaccines, Article, Autoimmune Diseases, 03 medical and health sciences, Immune system, MESH : Autoimmune Diseases, MESH: Mice, Inbred C57BL, MESH : Mice, MESH: Autoimmunity, medicine, Animals, Humans, Inhibins, Amino Acid Sequence, MESH: Mice, 030304 developmental biology, MESH: Molecular Sequence Data, MESH: Humans, MESH : Inhibins, business.industry, MESH : Ovarian Neoplasms, MESH : Peptide Fragments, MESH : Humans, MESH: Inhibins, medicine.disease, MESH : Disease Models, Animal, Peptide Fragments, Mice, Inbred C57BL, Disease Models, Animal, MESH : Cell Growth Processes, Immunology, biology.protein, Cancer vaccine, MESH : Animals, MESH: Disease Models, Animal, business, MESH: Female
Abstract

International audience; OBJECTIVES: An immune response sufficient to induce organ failure may provide protection and therapy against tumors derived from the targeted organ particularly when removal or ablation of the organ is part of the standard therapy and does not threaten survival. We have previously shown that a targeted immune response directed against the ovarian-specific protein, inhibin-α, causes ovarian failure. Here we determined whether inhibin-α autoimmunity is effective in both prevention and treatment of ovarian tumors. METHODS: A transgene consisting of the SV40 large tumor transformation antigen under the regulation of an anti-Mullerian hormone promoter (AMH-SV40Tag) was transferred by backcrossing for 12 generations to SJL/J mice producing SJL.AMH-SV40Tag (H-2(s)) females that develop a high incidence of autochthonous granulosa cell tumors. We determined whether immunization of SJL.AMH-SV40Tag female mice with the IA(s)-restricted p215-234 peptide of mouse inhibin-α was capable of preventing and treating these ovarian tumors. RESULTS: The growth of autochthonous ovarian granulosa cell tumors in SJL.AMH-SV40Tag transgenic mice was significantly inhibited in mice immunized with Inα 215-234. In addition, significant inhibition of tumor growth occurred when mice with established ovarian granulosa cell tumors were therapeutically vaccinated with Inα 215-234. CONCLUSIONS: Our results indicate that induction of ovarian-specific autoimmunity may serve as an effective way to prevent the emergence of autochthonous ovarian tumors and control the growth of established ovarian malignancies.

Published
2012
Full Text
View/download PDF

2. Regression of high-grade cervical intraepithelial neoplasia with TG4001 targeted immunotherapy

Author

Serge Douvier, Christine Clavel, Jean Lévêque, Patrick Raulic, Didier Riethmuller, Martine Baudin, Patrice Mathevet, Jean-Luc Brun, Valérie Calenda, Suzy Scholl, Bernard Huynh, Jean-Jacques Baldauf, Philippe Birembaut, Véronique Dalstein, Jean-Paul Bory, CHU Bordeaux [Bordeaux], Plasticité de l'épithélium respiratoire dans les conditions normales et pathologiques - UMR-S 903 ( PERPMP ), Université de Reims Champagne-Ardenne ( URCA ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -SFR CAP Santé (Champagne-Ardenne Picardie Santé), Université de Reims Champagne-Ardenne ( URCA ) -Université de Picardie Jules Verne ( UPJV ) -Université de Reims Champagne-Ardenne ( URCA ) -Université de Picardie Jules Verne ( UPJV ) -CHU de Reims - Hôpital Maison Blanche, Service de Gynécologie-Obstétrique, CHU Pontchaillou [Rennes], Service de gynécologie–obstétrique, CHU Strasbourg-Hôpital de Hautepierre [Strasbourg], Service de Génétique Oncologique, INSTITUT CURIE, Service de gynécologie obstétrique, Hôpital du Bocage, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon ) -Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon ), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), Plasticité de l'épithélium respiratoire dans les conditions normales et pathologiques - UMR-S 903 (PERPMP), Université de Reims Champagne-Ardenne (URCA)-Centre Hospitalier Universitaire de Reims (CHU Reims)-Institut National de la Santé et de la Recherche Médicale (INSERM)-SFR CAP Santé (Champagne-Ardenne Picardie Santé), Université de Reims Champagne-Ardenne (URCA)-Université de Reims Champagne-Ardenne (URCA), Service de Gynécologie et Obstétrique [Rennes] = Gynaecology [Rennes], Institut Curie [Paris], Service de Gynécologie Obstétrique, Médecine Foetale et Stérilité Conjugale - Chirurgie Gynécologie et Oncologique [CHU de Dijon], Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (UR 3181) (CEF2P / CARCINO), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV)-Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon)-Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Université de Reims Champagne-Ardenne ( URCA ) -Centre Hospitalier Universitaire de Reims ( CHU Reims ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -SFR CAP Santé (Champagne-Ardenne Picardie Santé), Université de Reims Champagne-Ardenne ( URCA ) -Université de Picardie Jules Verne ( UPJV ) -Université de Reims Champagne-Ardenne ( URCA ) -Université de Picardie Jules Verne ( UPJV ), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon ) -Hôpital du Bocage, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon ), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) ( CEF2P / CARCINO ), and Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté [COMUE] ( UBFC ) -Université de Franche-Comté ( UFC )

Subjects
MESH: Immunotherapy, Uterine Cervical Neoplasms, MESH : Cervical Intraepithelial Neoplasia, Gastroenterology, MESH: Cancer Vaccines, Targeted immunotherapy, 0302 clinical medicine, Cytology, MESH : Female, human papillomavirus, [ SDV.MHEP.GEO ] Life Sciences [q-bio]/Human health and pathology/Gynecology and obstetrics, MESH: Treatment Outcome, Colposcopy, 0303 health sciences, medicine.diagnostic_test, MESH : Cancer Vaccines, Obstetrics and Gynecology, virus diseases, female genital diseases and pregnancy complications, 3. Good health, MESH: Uterine Cervical Neoplasms, Treatment Outcome, MESH : Immunotherapy, 030220 oncology & carcinogenesis, MESH : Vaginal Smears, Female, Immunotherapy, medicine.symptom, medicine.medical_specialty, MESH: Vaginal Smears, MESH : Uterine Cervical Neoplasms, MESH : Treatment Outcome, [SDV.MHEP.GEO]Life Sciences [q-bio]/Human health and pathology/Gynecology and obstetrics, cervical intraepithelial neoplasia, Cervical intraepithelial neoplasia, Cancer Vaccines, Lesion, 03 medical and health sciences, Internal medicine, medicine, Humans, Human papillomavirus, 030304 developmental biology, Vaginal Smears, Gynecology, MESH: Humans, business.industry, MESH : Humans, Uterine Cervical Dysplasia, medicine.disease, Clinical trial, High Grade Cervical Intraepithelial Neoplasia, targeted immunotherapy, business, MESH: Cervical Intraepithelial Neoplasia, MESH: Female
Abstract

International audience; OBJECTIVE: We sought to evaluate the safety and efficacy of TG4001 in patients with human papillomavirus (HPV) 16-related cervical intraepithelial neoplasia (CIN) 2/3 at 6 and 12 months. STUDY DESIGN: In all, 21 patients with HPV 16-related CIN 2/3 received 3 weekly subcutaneous injections of TG4001. Regression of the CIN 2/3 lesion and the clearance of HPV 16 infection were monitored by cytology, colposcopy, and HPV DNA/messenger RNA (mRNA) detection. A clinical response was defined by no CIN 2/3 found on conization, or no conization performed because not suspected at cytology or colposcopy. RESULTS: Ten patients (48%) were evaluated as clinical responders at month 6. Nine patients experienced an improvement of their HPV 16 infection, by mRNA ± DNA eradication. HPV 16 mRNA clearance was associated with CIN 2/3 cytologic and colposcopic regression in 7 of 10 patients. At month 12, 7 of 8 patients without conization reported neither suspicion of CIN 2/3 relapse nor HPV 16 infection. The remaining patient was lost to follow-up. CONCLUSION: These promising data warrant further development of TG4001 in CIN 2/3 treatment.

Published
2011
Full Text
View/download PDF

3. Delivery of mengovirus-derived RNA replicons into tumoural liver enhances the anti-tumour efficacy of a peripheral peptide-based vaccine

Author

Sylvie van der Werf, Mireille Viguier, Carmen Marchiol, Didier Fradelizi, Anne-Marie Crain, Jean-Pierre Couty, Sarah Boudaly, Marilyne Labasque, Marco Vignuzzi, Catherine Guettier, Nicolas Escriou, Sylvie Gerbaud, Institut Cochin (UMR_S567 / UMR 8104), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5), Institut Cochin (IC UM3 (UMR 8104 / U1016)), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université Paris Descartes - Paris 5 (UPD5), Université Paris Diderot - Paris 7 (UPD7), Génétique Moléculaire des Virus Respiratoires, Institut Pasteur [Paris]-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS), Pathologie cellulaire : aspects moléculaires et viraux / Pathologie et Virologie Moléculaire, Institut Universitaire d'Hématologie (IUH), Université Paris Diderot - Paris 7 (UPD7)-Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Centre National de la Recherche Scientifique (CNRS), Laboratoire d'Anatomie Pathologique, Hôpital Paul Brousse, Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de la Recherche Scientifique (CNRS)-Université Paris Diderot - Paris 7 (UPD7)-Institut Pasteur [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS), Institut Pasteur [Paris] (IP)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS), Institut Cochin ( UMR_S567 / UMR 8104 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Institut Cochin ( UM3 (UMR 8104 / U1016) ), Université Paris Descartes - Paris 5 ( UPD5 ), Université Paris Diderot - Paris 7 ( UPD7 ), Institut Pasteur [Paris]-Université Paris Diderot - Paris 7 ( UPD7 ) -Centre National de la Recherche Scientifique ( CNRS ), Laboratoire d'Immunologie Cellulaire et Immunopathologie de l'Ecole Pratique des Hautes Etudes, Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Université Paris Diderot - Paris 7 (UPD7)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
Male, MESH : Prevalence, MESH: Immunotherapy, medicine.medical_treatment, MESH: Flow Cytometry, Epitope, MESH: Cancer Vaccines, Mice, 0302 clinical medicine, MESH: Liver Neoplasms, Cytotoxic T cell, MESH: Animals, Replicon, MESH : Influenza A Virus, H9N2 Subtype, MESH: Phylogeny, MESH: Treatment Outcome, 0303 health sciences, MESH : Peptides, MESH: Peptides, Liver Neoplasms, MESH : Reverse Transcriptase Polymerase Chain Reaction, Flow Cytometry, MESH : Influenza in Birds, 3. Good health, MESH : Influenza A virus, MESH : Immunotherapy, Oncology, MESH: RNA, Viral, MESH : Animal Migration, Immunotherapy, Carcinoma, Hepatocellular, T cell, Immunology, MESH: Replicon, 03 medical and health sciences, MESH: Species Specificity, MESH: Animals, Wild, MESH : Birds, MESH: Prevalence, Histocompatibility Antigens Class I, Mengovirus, RNA, MESH : Disease Models, Animal, Mice, Inbred C57BL, MESH: Disease Models, Animal, Peptides, MESH: Female, Cancer Research, MESH : Liver Neoplasms, MESH : Mengovirus, MESH: Histocompatibility Antigens Class I, MESH: Reverse Transcriptase Polymerase Chain Reaction, Immunology and Allergy, MESH : Female, MESH: Carcinoma, Hepatocellular, MESH : Animals, Wild, MESH : Cloaca, biology, MESH : Cancer Vaccines, MESH: Animal Migration, medicine.anatomical_structure, Treatment Outcome, MESH: Birds, MESH: Sentinel Surveillance, RNA, Viral, MESH : Histocompatibility Antigens Class I, MESH : Replicon, MESH : Carcinoma, Hepatocellular, MESH : Sentinel Surveillance, MESH : Flow Cytometry, MESH : Male, MESH: Influenza A virus, MESH : Mice, Inbred C57BL, MESH : Treatment Outcome, Cancer Vaccines, MESH: Influenza in Birds, MESH: Mice, Inbred C57BL, MESH : Mice, medicine, MESH : Species Specificity, MESH : RNA, Viral, Animals, MESH : France, MESH: Mice, 030304 developmental biology, MESH : Phylogeny, biology.organism_classification, MESH: Male, MESH: Cloaca, MESH: Influenza A Virus, H9N2 Subtype, MESH: France, Disease Models, Animal, MESH : Animals, CD8, MESH: Mengovirus, 030215 immunology
Abstract

International audience; Hepatocellular carcinoma is a deadly cancer with growing incidence for which immunotherapy is one of the most promising therapeutic approach. Peptide-based vaccines designed to induce strong, sustained CD8+ T cell responses are effective in animal models and cancer patients. We demonstrated the efficacy of curative peptide-based immunisation against a unique epitope of SV40 tumour antigen, through the induction of a strong CD8+ T cell-specific response, in our liver tumour model. However, as in human clinical trials, most tumour antigen epitopes did not induce a therapeutic effect, despite inducing strong CD8+ T cell responses. We therefore modified the tumour environment to enhance peptide-based vaccine efficacy by delivering mengovirus (MV)-derived RNA autoreplicating sequences (MV-RNA replicons) into the liver. The injection of replication-competent RNA replicons into the liver converted partial tumour regression into tumour eradication, whereas non-replicating RNA had no such effect. Replicating RNA replicon injection induced local recruitment of innate immunity effectors (NK and NKT) to the tumour and did not affect specific CD8+ T cell populations or other myelolymphoid subsets. The local delivery of such RNA replicons into tumour stroma is therefore a promising strategy complementary to the use of peripheral peptide-based vaccines for treating liver tumours.

Published
2008
Full Text
View/download PDF

4. Human papillomavirus genotype distribution in high grade cervical lesions (CIN 2/3) in France: EDITH study

Author

Prétet , Jean-Luc, Jacquard , Anne-Carole, Carcopino , Xavier, Monnier-Benoit , Sylvain, Averous , Gerlinde, Soubeyrand , Benoit, Leocmach , Yann, Mougin , Christiane, Riethmuller , Didier, Renseigné , Non, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), and Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC )

Subjects
Adult, Risk, MESH : Retrospective Studies, Genotype, MESH : Prevalence, MESH : Risk, MESH : Uterine Cervical Neoplasms, MESH : Aged, Uterine Cervical Neoplasms, MESH : Genotype, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH : Cervical Intraepithelial Neoplasia, Cancer Vaccines, MESH: Cancer Vaccines, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, MESH: Genotype, MESH : Precancerous Conditions, MESH: Papillomaviridae, Prevalence, Humans, MESH : Female, MESH : Middle Aged, MESH : France, MESH : Papillomaviridae, Papillomaviridae, MESH: Prevalence, Aged, Retrospective Studies, MESH: Aged, MESH: Risk, MESH: Humans, MESH: Middle Aged, MESH : Humans, MESH : Cancer Vaccines, virus diseases, MESH: Adult, MESH: Retrospective Studies, MESH : Adult, Middle Aged, Uterine Cervical Dysplasia, female genital diseases and pregnancy complications, MESH: Uterine Cervical Neoplasms, MESH: France, MESH: Precancerous Conditions, Female, France, MESH: Cervical Intraepithelial Neoplasia, Precancerous Conditions, MESH: Female
Abstract

International audience; High grade cervical intraepithelial neoplasia (CIN 2/3) have a high potential to progress to invasive cervical cancer (ICC). Pap testing including follow-up and treatment of CIN 2/3 is currently the best prevention of ICC, but is associated with morbidity, namely obstetrical adverse effects and psychological distress. Human papillomavirus (HPV) is universally accepted as the necessary cause of ICC. The objective of the present study was to describe the type-specific prevalence of HPV in CIN 2/3 in France and hereby to locally estimate the potential benefit of an HPV 16/18 L1 virus-like particles (VLP) vaccine. A total of 493 formalin-fixed and paraffin-embedded CIN 2/3 specimens were analyzed. Medical records were examined for patient related data. HPV were genotyped with the INNO-LiPA assay allowing the detection of 24 HPV genotypes. The overall prevalence of LiPA detectable HPV was 98%. The most prevalent genotype was HPV 16 (62%) followed by HPV 31 (15%), 33 (12%), 52 (9%), 51 (8%), 58 (7%), 35 and 18 (4%). Multiple infection with at least two different high-risk (HR) HPV genotypes was observed in 26% of all specimens including 2.6% with HPV 16 and 18 multiple infections. The present study indicates that HPV 16 is by far the most common HPV type associated with CIN 2/3 in France. With an HPV 16 and 18 prevalence of 64%, HPV 16/18 L1 VLP vaccines would be expected to significantly reduce the burden associated with the management and treatment of CIN 2/3 in France.

Published
2008
Full Text
View/download PDF

5. Human papillomavirus (HPV) genotype distribution in invasive cervical cancers in France: EDITH study

Author

Prétet, Jean-Luc, Jacquard, Anne-Carole, Carcopino, Xavier, Charlot, Jean-François, Bouhour, Damien, Kantelip, Bernadette, Soubeyrand, Benoit, Leocmach, Yann, Mougin, Christiane, Riethmuller, Didier, Renseigné, Non, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Service d'Anatomie pathologique [CHRU Besançon], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), Laboratoire d'anatomie pathologique [Besancon], and Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Hôpital Jean Minjoz-Université de Franche-Comté ( UFC )

Subjects
Adult, Risk, Genotype, MESH : Prevalence, MESH : Risk, MESH : Uterine Cervical Neoplasms, MESH : Aged, Uterine Cervical Neoplasms, MESH : Genotype, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH : Cervical Intraepithelial Neoplasia, Cancer Vaccines, MESH: Cancer Vaccines, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, MESH: Genotype, MESH : Precancerous Conditions, MESH: Papillomaviridae, Prevalence, Humans, MESH : Female, MESH : Middle Aged, MESH : France, MESH : Papillomaviridae, Papillomaviridae, MESH: Prevalence, Aged, MESH: Aged, MESH: Risk, MESH: Humans, MESH: Middle Aged, MESH : Humans, MESH : Cancer Vaccines, virus diseases, MESH: Adult, Middle Aged, MESH : Adult, Uterine Cervical Dysplasia, female genital diseases and pregnancy complications, MESH: Uterine Cervical Neoplasms, MESH: France, MESH: Precancerous Conditions, Female, France, MESH: Cervical Intraepithelial Neoplasia, Precancerous Conditions, MESH: Female
Abstract

International audience; Invasive cervical cancer (ICC) remains a significant cause of morbidity and mortality in France. Since human papillomavirus (HPV) is the necessary cause of ICC, the aim of this study was to assess the type-specific prevalence of HPV in ICC in France in order to locally evaluate the potential benefit of an HPV 16/18 L1 virus-like particles (VLP) vaccination. A total of 516 histological specimens collected in 15 centers were analyzed. Among them, 86% had a diagnosis of squamous cell carcinoma (SCC) whereas 14% were adenocarcinomas (ADC). HPV genotyping was performed using the INNO-LiPA assay allowing the specific detection of 24 HPV genotypes both high risk (HR) and low risk (LR). The overall HPV prevalence in ICC was 97%. The most prevalent genotypes were HPV 16 (73%) and HPV 18 (19%) followed by HPV 31 (7%), 33, 68, 45, 52 and 58 (4.1-2.3%). HPV 16 and/or 18 were associated with 82% of ICC, 10% being HPV 16 and 18 coinfections. While HPV 16 was the most prevalent type in both SCC (74%) and ADC (64%), HPV 18 was by far more prevalent in ADC (37%) compared to SCC (16%; p < 0.001). Multiple infections with at least two different HR HPV genotypes were observed in 22% of ICC. Given the high HPV 16/18 prevalence and taking into account possible production of crossneutralizing antibodies against other HPV types, HPV 16/18 L1 VLP vaccination would be expected to significantly reduce the burden of ICC in France.

Published
2008
Full Text
View/download PDF

6. [Prophylactic and therapeutic vaccination against human papillomavirus]

Author

Brun , J.-L., Riethmuller , D., Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), and Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC )

Subjects
MESH : Cell Line, MESH : RNA, Messenger, MESH: Vaccines, Synthetic, MESH : Uterine Cervical Neoplasms, MESH : Toll-Like Receptor 3, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH : Papillomavirus Vaccines, MESH : Toll-Like Receptor 7, MESH: Guanosine, MESH: Papillomavirus Infections, MESH: Poly I-C, MESH: Cancer Vaccines, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, MESH : Interferon-beta, MESH: Papillomaviridae, MESH : Gene Silencing, MESH : Mice, MESH : Female, MESH: Animals, MESH: Gene Silencing, MESH : Papillomaviridae, MESH : Vaccines, Synthetic, MESH: Mice, MESH : Macrophages, MESH: RNA, Messenger, MESH : Papillomavirus Infections, MESH: Interleukin-23, MESH: Humans, MESH : Gene Expression Regulation, MESH: Interferon-beta, MESH : Humans, MESH : Cancer Vaccines, MESH : Guanosine, MESH: Macrophages, MESH: Papillomavirus Vaccines, MESH : Theilovirus, MESH: Toll-Like Receptor 3, MESH: Gene Expression Regulation, MESH: Cell Line, MESH: Toll-Like Receptor 7, MESH: Uterine Cervical Neoplasms, MESH: Theilovirus, MESH : Interleukin-23, MESH : Animals, MESH: Female, MESH : Poly I-C
Abstract

International audience; Human papillomavirus is a necessary cause for the development of cervical cancer. Cervical cancer is attributed to 15 high-risk oncogenic HPV among the 120 genotypes present in human. The infection affects about 3 out of 4 women and is often transient thanks to immunological modulators leading to viral clearance. This characteristic made it possible to develop vaccines. Prophylactic vaccines are made of virus-like particles L1, non infectious, well tolerated and highly immunogenic. They prevent from viral infection by producing antibodies, which are secreted throughout the genital mucosa (humoral immunity). High-risk oncogenic HPV-16 and 18, responsible for 70% of cervical cancer, are included in Gardasil and Cervarix. Both vaccines prevent from HPV infection and related cervical and perineal lesions in more than 90% of the cases. Therapeutic vaccines are made of epitope peptides, recombinant proteins and bacteria, plasmid DNA or dendritic cells. All sensitize immunocompetent cells (cellular immunity). Ineffective in cervical cancers, they induce the regression of cervical dysplasia in about 50% of the cases. They are still under research and development, in opposition to prophylactic vaccines, which are available.

Published
2007
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results